Observational studyGynecologic oncology2021
Prospective analysis of circulating metabolites and endometrial cancer risk.
Registry-linked trialOpen access · hybridAbstract readMulticenter StudyObservational Study
In one paragraph
Observational study in Gynecologic oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07262593 (Family-Based Meal Timing for Cancer Prevention Among Native Hawaiian and Other Pacific Islanders), which is not on this map. Cited by 25 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Family-Based Meal Timing for Cancer Prevention Among Native Hawaiian and Other Pacific Islanders: FAMTIME
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- The underexplored links between cancer and the internal body climate: Implications for cancer prevention and treatment.Frontiers in oncology · 2022Pooled it
- Blood-based obesity biomarkers and their relevance for disease risk.Nature reviews. Endocrinology · 2026Review
- Development and validation of hypermethylated gene markers in cervical cytological samples for detecting endometrial cancer (EndoMethy-I trial).Frontiers in oncology · 2026Article
- The "serine code" of metabolic reprogramming: multidimensional roles of the serine synthesis pathway in tumors and novel breakthroughs for targeted therapy.Frontiers in immunology · 2026Review
- Metabolomics reveals the therapeutic efficacy of liposomal resvida in endometrial cancer through regulating autophagy-related gene expression.Cancer cell international · 2025Article
- Adiposity, metabolites and endometrial cancer risk: inference from combinations of Mendelian randomization and observational analyses.BMC cancer · 2025Observational
- Glutaminase as a metabolic target of choice to counter acquired resistance to Palbociclib by colorectal cancer cells.Oncogene · 2025Article
- Detecting metabolic signatures in endometrial cancer: potential applications of Raman spectroscopy.Future oncology (London, England) · 2025Review
- Unlocking the Potential of Liquid Biopsy: A Paradigm Shift in Endometrial Cancer Care.Diagnostics (Basel, Switzerland) · 2025Review
- Metabolic profile of biodiverse diets in a healthy European cohort.The American journal of clinical nutrition · 2025Article
- Metabolism pathway-based subtyping in endometrial cancer: An integrated study by multi-omics analysis and machine learning algorithms.Molecular therapy. Nucleic acids · 2024Article
- Resveratrol activates MAPK/ERK pathway to regulate oestrogen metabolism in type I endometrial cancer.BMC complementary medicine and therapies · 2024Article
- Metabolomic Profiling of Blood Plasma in Females with Hyperplasia and Endometrial Cancer.Metabolites · 2024Article
- Urine and serum metabolomic analysis of endometrial cancer diagnosis and classification based on ultra-performance liquid chromatography mass spectrometry.Metabolomics : Official journal of the Metabolomic Society · 2024Article
- Metabolomic biomarkers in liquid biopsy: accurate cancer diagnosis and prognosis monitoring.Frontiers in oncology · 2024Review
- Evaluation of the impact of diabetes mellitus on endometrial cancer risk: an updated meta-analysis of case-control studies.Archives of medical science : AMS · 2024Article
- Profile Characterization of Biogenic Amines in Glioblastoma Patients Undergoing Standard-of-Care Treatment.Biomedicines · 2023Article
- Dietary Inflammatory and Insulinemic Potentials, Plasma Metabolome and Risk of Colorectal Cancer.Metabolites · 2023Article
- Endometrial cancer diagnostic and prognostic algorithms based on proteomics, metabolomics, and clinical data: a systematic review.Frontiers in oncology · 2023Review
- Pan-cancer analysis of pre-diagnostic blood metabolite concentrations in the European Prospective Investigation into Cancer and Nutrition.BMC medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
36 authors at 18 institutions in 10 countries.
Laure DossusNutrition and Metabolism Section, International Agency for Research on Cancer, Lyon, France. Electronic address: dossusl@iarc.fr.
Eirini KoulouraCancer Metabolism and Systems Toxicology Group, Division of Cancer, Department of Surgery and Cancer, Imperial College, London, UK; European Food Safety Authority, Via Carlo Magno 1A, 43126 Parma, Italy.
Carine BiessyNutrition and Metabolism Section, International Agency for Research on Cancer, Lyon, France.
Vivian ViallonNutrition and Metabolism Section, International Agency for Research on Cancer, Lyon, France.
Alexandros P SiskosCancer Metabolism and Systems Toxicology Group, Division of Cancer, Department of Surgery and Cancer, Imperial College, London, UK.
Niki DimouNutrition and Metabolism Section, International Agency for Research on Cancer, Lyon, France.
Sabina RinaldiNutrition and Metabolism Section, International Agency for Research on Cancer, Lyon, France.
Melissa A MerrittCancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI, USA.
Naomi AllenNuffield Department of Population Health, University of Oxford, Oxford, UK.
Renee FortnerDivision of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Rudolf KaaksDivision of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Elisabete WeiderpassOffice of the Director, International Agency for Research on Cancer, Lyon, France.
Inger T GramDepartment of Community Medicine, Faculty of Health Sciences, University of Tromsø, The Arctic University of Norway, Troms, Norway.
Joseph A RothwellCentre for Research in Epidemiology and Population Health, CESP, Université Paris-Saclay, UVSQ, Inserm U1018, Villejuif, France; Gustave Roussy, Villejuif, France.
Lucie LécuyerCentre for Research in Epidemiology and Population Health, CESP, Université Paris-Saclay, UVSQ, Inserm U1018, Villejuif, France; Gustave Roussy, Villejuif, France.
Gianluca SeveriCentre for Research in Epidemiology and Population Health, CESP, Université Paris-Saclay, UVSQ, Inserm U1018, Villejuif, France; Gustave Roussy, Villejuif, France; Department of Statistics, Computer Science and Applications "G. Parenti" (DISIA), University of Florence, Italy.
Matthias B SchulzeDepartment of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany; Institute of Nutritional Science, University of Potsdam, Potsdam, Germany.
Therese Haugdahl NøstDepartment of Community Medicine, Faculty of Health Sciences, University of Tromsø, The Arctic University of Norway, Troms, Norway.
Marta Crous-BouUnit of Nutrition and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO), Barcelona, Spain; Nutrition and Cancer Group, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston,USA.
Maria-Jose SánchezEscuela Andaluza de Salud Pública (EASP), Granada, Spain; Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain; Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain; Department of Preventive Medicine and Public Health, University of Granada, Granada, Spain.
Pilar AmianoCentro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain; Public Health Division of Gipuzkoa, BioDonostia Research Institute, Donostia-San Sebastian, Spain.
Sandra M Colorado-YoharCentro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain; Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, Murcia, Spain; Research Group on Demography and Health, National Faculty of Public Health, University of Antioquia, Medellín, Colombia.
Aurelio Barricarte GurreaCentro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain; Navarra Public Health Institute, Pamplona, Spain; Navarra Institute for Health Research (IdiSNA) Pamplona, Spain.
Julie A SchmidtCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Domenico PalliInstitute for Cancer Research, Prevention and Clinical Network - ISPRO, Cancer Risk Factors and Life-Style Epidemiology Unit, Florence, Italy.
Claudia AgnoliEpidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy.
Rosario TuminoCancer Registry and Histopathology Department, Provincial Health Authority (ASP) Ragusa, Italy.
Carlotta SacerdoteUnit of Cancer Epidemiology, Città della Salute e della Scienza University-Hospital and Center for Cancer Prevention (CPO), Turin, Italy.
Amalia MattielloDipartimento di Medicina Clinica e Chirurgia, Federico II University, Naples, Italy.
Roel VermeulenInstitute for Risk Assessment Sciences, Utrecht University, Utrecht, the Netherlands.
Alicia K HeathDepartment of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.
Sofia ChristakoudiDepartment of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK; MRC Centre for Transplantation, King's College London, London, UK.
Konstantinos K TsilidisDepartment of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK; Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece.
Ruth C TravisCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Marc J GunterNutrition and Metabolism Section, International Agency for Research on Cancer, Lyon, France.
Hector C KeunCancer Metabolism and Systems Toxicology Group, Division of Cancer, Department of Surgery and Cancer, Imperial College, London, UK.
Centre International de Recherche sur le Cancer · FRImperial College London · GBUniversity of Oxford · GBCentre de recherche en Epidémiologie et Santé des Populations · FRCentro de Investigación Biomédica en Red de Epidemiología y Salud Pública · ESHeidelberg University · DEPiedmont Reference Center for Epidemiology and Cancer Prevention · ITUiT The Arctic University of Norway · NOBiogipuzkoa Health Research Institute · ESBoston University · USFederico II University Hospital · ITFondazione IRCCS Istituto Nazionale dei Tumori · ITKing's College London · GBUniversidad de Granada · ESUniversité de Versailles Saint-Quentin-en-Yvelines · FRUniversity of Hawaii Cancer CenterUniversity of Potsdam · DEUtrecht University · NL
Funding
Cancer Research UK 16896Cancer Research UK 21351Cancer Research UK 29017Cancer Research UK C19335/A21351Medical Research Council MR/M012190/1World Health Organization 001
Abstract
backgroundEndometrial cancer is strongly associated with obesity and dysregulation of metabolic factors such as estrogen and insulin signaling are causal risk factors for this malignancy. To identify additional novel metabolic pathways associated with endometrial cancer we performed metabolomic analyses on pre-diagnostic plasma samples from 853 case-control pairs from the European Prospective Investigation into Cancer and Nutrition (EPIC).
methodsA total of 129 metabolites (acylcarnitines, amino acids, biogenic amines, glycerophospholipids, hexoses, and sphingolipids) were measured by liquid chromatography-mass spectrometry. Conditional logistic regression estimated the associations of metabolites with endometrial cancer risk. An analysis focusing on clusters of metabolites using the bootstrap lasso method was also employed.
resultsAfter adjustment for body mass index, sphingomyelin [SM] C18:0 was positively (OR
conclusionThese findings suggest that variation in levels of glycine, serine, SM C18:0 and free carnitine may represent specific pathways linked to endometrial cancer development. If causal, these pathways may offer novel targets for endometrial cancer prevention.
Indexed as
AgedBiomarkers, TumorBody Mass IndexCarnitineCase-Control StudiesEndometrial NeoplasmsFemaleGlycineHumansMetabolomicsMiddle AgedProspective StudiesRisk FactorsSerineSphingomyelinsBiomarkers, TumorCarnitineGlycineSerineSphingomyelinsAmino acidsEndometrial cancerLipidsMetabolomicsObesity
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
NCT07262593ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.